Science
Mechanism of Action
This ingredient operates on multiple physiological levels to support skin health. It bolsters the skin's barrier function by fostering the growth of beneficial Staphylococcus epidermidis and increasing antimicrobial peptide expression within human epidermal keratinocytes. It reduces stratifin, preventing the decline of filaggrin and serine palmitoyltransferase, crucial for maintaining epidermal moisture. By suppressing the inflammatory cytokine IL-6, it may reduce collagen degradation and elastic fiber damage by matrix metalloproteinases (MMPs), thereby mitigating wrinkle formation. Its composition of essential amino acids, antioxidative enzymes, and nucleic acids contributes to improved elasticity and overall skin revitalization. Furthermore, it actively reduces melanin synthesis and content, offering protection against UV-induced pigmentation, and enhances surface hydration while reducing trans-epidermal water loss (TEWL) through film formation. In vitro studies confirm its ability to activate mitochondrial activity in human fibroblasts, promoting Type I collagen synthesis, alongside exhibiting strong antioxidant, UV-protective, and anti-inflammatory effects. It also aids in wound healing by promoting cell proliferation and regulating collagen metabolism.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 A topical cream utilizing horse placental extract as a primary ingredient demonstrated a reduction in eye-corner wrinkles (both maximum width and number) in healthy women aged 37-54 over a 2-week period.
- 02 Oral supplementation of 220 mg of equine placental extract daily for 4 weeks significantly decreased the melanin index and provided protection against UV-induced pigmentation on the cheek skin of healthy women aged 30-59.
- 03 In vitro, horse placental peptides at 500 µg/mL markedly enhanced mitochondrial activity in human fibroblasts, leading to increased production of type I collagen.
- 04 In vitro assays revealed strong antioxidant capabilities of horse placental peptides at concentrations of 75 µg/mL and 150 µg/mL.
Transparency
Dusting Analysis
Given the diverse range of demonstrated benefits in both human and in-vitro studies, including significant anti-aging and pigmentation effects, this ingredient is unlikely to be used merely as a token addition for marketing purposes.
The Formula
Formulation
Stability
For optimal stability and efficacy, this ingredient should be incorporated during the final phase of formulation. Processing temperatures must not exceed 40°C. Raw materials require stringent quality control, robust hygiene protocols, and heat treatment to ensure the inactivation of potential viruses. The final product must be free from detectable pathogenic viruses, infectious agents, and any metabolic or endocrine activity.
Safety
Safety Profile
The Cosmetic Ingredient Review (CIR) Expert Panel has determined that data are insufficient to support the safety of this broad category of ingredients in cosmetics. Regulatory bodies require that such ingredients be devoid of any metabolic or endocrine activity and be rigorously tested to ensure they are free from pathogenic viruses or infectious agents. European Union Cosmetics Regulation 1223/2009, Annex II, entry 419, specifically prohibits Category 1 and 2 animal material and their derivatives in cosmetic products, necessitating careful consideration of sourcing and processing to comply with these restrictions. Some manufacturers assert their horse placenta products are free from FDA-prohibited hormones.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While displaying promising clinical evidence for wrinkle reduction and pigmentation control, the 'insufficient data' status from CIR and complex regulatory considerations necessitate further comprehensive safety assessments before a definitive verdict can be made for cosmetic use.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources